

# MARKET REPORT



## PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

## Summary

GlobalData estimates sales of Heart Failure (HF) therapeutics to be approximately \$3.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The HF market will grow at a strong CAGR of 13.5% over the forecast period, reaching sales of \$11.5B by 2025. The 7MM chronic HF market size in 2015 was \$3.1B, and is expected to increase to \$10.1B by 2025 at a CAGR of 12.7%. The US was the largest market for chronic HF therapies, contributing 61.2% of total sales in the base year. GlobalData expects uptake of Novartis' Entresto to be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of \$5.9B in 2022. The acute HF market is expected to increase from just \$188.1M in 2015 to \$1.5B in 2025, at a CAGR of 23.0%. Japan dominated the acute HF market in the base year, 2015, accounting for 86.0% of market share. However, with the launch of several acute HF add-on therapies in the forecast period, the US will take over as the acute HF market leader, contributing 68.7% of sales to the acute HF market by 2025.

## Highlights

### Key Questions Answered

- The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfil these unmet needs of the market? Key Opinion Leaders (KOLs) interviewed by GlobalData provide insights and highlight opportunities for drug developers.
- The HF market is crowded with cheap, generic, "me-too" drugs, making it a particularly difficult market to penetrate. The current late-stage pipeline consists of several chronic HF therapies, and three novel acute HF therapies. How will the market be impacted by the launch of these drugs? Which of the marketed and pipeline drugs will have the highest peak sales at the highest CAGR, and why?
- Will Entresto become the new standard-of-care in the chronic HF market? What are the main barriers a new therapy faces when entering the HF market?

### Key Findings

- The major drivers for growth across the 7MM in the HF market during the forecast period will be the launch of the first-in-class angiotensin receptor blocker/neprilysin inhibitor (ARNi), Entresto, marketed by Novartis, as well as the launches of two acute HF therapies, Cardioentis' ularitide and Novartis' serelaxin.
- KOLs interviewed by GlobalData opined that Entresto has potential to replace ACE inhibitors as the first-line therapy for HF, however they expect this to occur towards the end of the forecast period.
- In other interviews, KOLs highlighted that the greatest unmet need in the HF disease space is the need to develop efficacious therapies for HF with preserved ejection fraction (HF-PEF) and acute HF.
- High cost of new drugs and the reluctance of cardiologists to prescribe these new drugs are the major barriers for growth in the HF market during the forecast period.

## Scope

- Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

## Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM HF therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

## Additional Details

**Publisher** : Global Data

**Reference** : GDHC127PIDR

**Number of Pages** : 383

**Report Format** : PDF

**Publisher Information** :

**GlobalData»**

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

- 1 Table of Contents1 Table of Contents 101.1 List of Tables 171.2 List of Figures 222 Introduction 242.1 Catalyst 242.2 Related Reports 243 Disease Overview 253.1 Etiology and Pathophysiology 253.1.1 Etiology 253.2 Classification and Staging Systems 323.3 Symptoms 333.4 Prognosis 343.5 Quality of Life 354 Epidemiology 374.1 Disease Background 374.2 Risk Factors and Comorbidities 384.3 Global Trends 404.3.1 US 404.3.2 5EU 414.3.3 Japan 424.4 Forecast Methodology 424.4.1 Sources Used 454.4.2 Forecast Assumptions and Methods 484.4.3 Sources Not Used 634.5 Epidemiological Forecast for HF (2015-2025) 634.5.1 Diagnosed Incident Cases 634.5.2 Diagnosed Prevalent Cases 774.6 Discussion 894.6.1 Epidemiological Forecast Insight 894.6.2 Limitations of the Analysis 894.6.3 Strengths of the Analysis 905 Disease Management 915.1 Diagnosis and Treatment Overview 915.1.1 Diagnosis 915.1.2 Treatment Guidelines and Leading Prescribed Drugs 945.1.3 Medical Devices 995.1.4 Clinical Practice 1005.2 US 1065.3 5EU 1085.4 Japan 1126 Competitive Assessment 1156.1 Overview 1156.2 Drug Profiles 1166.2.1 Angiotensin-Converting Enzyme Inhibitors 1166.2.2 Angiotensin Receptor Blockers 1226.2.3 Entresto (sacubitril + valsartan) 1266.2.4 Diuretics 1416.2.5 Beta Blockers 1466.2.6 Procoralan (ivabradine) 1506.2.7 Mineralocorticoid Receptor Antagonists 1586.2.8 Digoxin 1626.2.9 Pharmacological Therapies for Acute HF 1657 Unmet Needs and Opportunities 1687.1 Overview 1687.1.1 Acute HF - Target Opportunity Profile 1707.1.2 HF with Preserved Ejection Fraction - Target Opportunity Profile 1737.1.3 HF with Reduced Ejection Fraction - Target Opportunity Profile 1767.2 Lack of Therapies for HF with Preserved Ejection Fraction Patients 1817.2.1 Unmet Need 1817.2.2 Gap Analysis 1827.2.3 Opportunity 1837.3 Lack of Therapies for Acute HF 1837.3.1 Unmet Need 1837.3.2 Gap analysis 1847.3.3 Opportunity 1857.4 Lack of Therapies for Acute HF Patients Experiencing Diuretic Resistance 1867.4.1 Unmet Need 1867.4.2 Gap Analysis 1877.4.3 Opportunity 1887.5 Lack of Therapies for Patients with Renal Impairment 1887.5.1 Unmet Need 1887.5.2 Gap Analysis 1897.5.3 Opportunity 1897.6 Treatment of Patients with Multiple Comorbidities 1907.6.1 Unmet Need 1907.6.2 Gap Analysis 1917.6.3 Opportunity 1917.7 Enhanced Diagnosis and Preventative Therapies for Patients at Risk of Developing HF 1927.7.1 Unmet Need 1927.7.2 Gap Analysis 1937.7.3 Opportunity 1947.8 Conducting Clinical Trials in Cohorts of Japanese Patients 1957.8.1 Unmet Need 1957.8.2 Gap Analysis 1967.8.3 Opportunity 1967.9 Use of Optimal Doses of HF Therapies 1977.9.1 Unmet Need 1977.9.2 Gap Analysis 1987.9.3 Opportunity 1997.10 Patient Compliance 1997.10.1 Unmet Need 1997.10.2 Gap Analysis 2007.10.3 Opportunity 2017.11 Early Detection and Treatment of Patients with Worsening Chronic HF 2017.11.1 Unmet Need 2017.11.2 Gap Analysis 2027.11.3 Opportunity 2037.12 Dynamic Management of Patients with HF 2037.12.1 Unmet Need 2037.12.2 Gap Analysis 2057.12.3 Opportunity 2057.13 Options for Advanced HF Patients Who Are Unable to Receive a Heart Transplant 2067.13.1 Unmet Need 2067.13.2 Gap Analysis 2077.13.3 Opportunity 2078 Pipeline Assessment 2088.1 Overview 2088.2 Promising Drugs in Late-Stage Clinical Development 2108.2.1 Serelaxin 2128.2.2 Ularitide 2218.2.3 Omecamtiv Mecarbil 2298.2.4 Vericiguat 2388.2.5 Finerenone 2458.2.6 Neucardin 2518.2.7 Revatio 2558.3 Promising Drugs in Early Stage Development 2598.3.1 CXL-1427 2598.3.2 Istaroxime 2608.3.3 Perhexiline Maleate 2608.3.4 TRV-027 2618.4 Other Drugs in Development 2619 Current and Future Players 2639.1 Overview 2639.2 Trends in Corporate Strategy 2659.3 Company Profiles 2669.3.1 Novartis 2669.3.2 Les Laboratoires Servier 2699.3.3 Cardiorentis 2719.3.4 Bayer (and Merck & Co.) 2729.3.5 Cytokinetics 27410 Market Outlook 27610.1 Global Markets 27610.1.1 Forecast 27610.1.2 Drivers and Barriers - Global Issues 28110.2 US 28510.2.1 Forecast 28510.2.2 Key Events 28910.2.3 Drivers and Barriers 29010.3 France 29110.3.1 Forecast 29110.3.2 Key Events 29510.3.3 Drivers and Barriers 29610.4 Germany 29710.4.1 Forecast 29710.4.2 Key Events 30010.4.3 Drivers and Barriers 30110.5 Italy 30210.5.1 Forecast 30210.5.2 Key Events 30510.5.3 Drivers and Barriers 30610.6 Spain 30710.6.1 Forecast 30710.6.2 Key Events 31010.6.3 Drivers and Barriers 31110.7 UK 31210.7.1 Forecast 31210.7.2 Key Events 31510.7.3 Drivers and Barriers 31610.8 Japan 31710.8.1 Forecast 31710.8.2 Key Events 32110.8.3 Drivers and Barriers 32111 Appendix 32411.1 Bibliography 32411.2 Abbreviations 35611.3 Methodology 36411.4 Forecasting Methodology 36411.4.1 Diagnosed Prevalent Chronic HF 36411.4.2 Diagnosed Incidence of Acute HF 36511.4.3 Percent Drug-Treated Patients 36511.4.4 Treatment of HF with Reduced Ejection Fraction Versus HF with Preserved Ejection Fraction 36511.4.5 Drugs Included in Each Therapeutic Class 36511.4.6 Launch and Patent Expiry Dates 36611.4.7 General Pricing Assumptions 36711.4.8 Individual Drug Assumptions 36811.4.9 Generic Erosion 37311.4.10 Pricing of Pipeline Agents 37311.5 Key Opinion Leaders Included in This Study 37511.6 Payers Included in This Study 37711.7 High-Prescribing Physician Survey 37811.8 About the Authors 37911.8.1

Author 37911.8.2 Contributing Author 37911.8.3 Therapy Area Director 37911.8.4 Epidemiologist 38011.8.5  
Global Director of Therapy Analysis and Epidemiology 38011.8.6 Global Head of Healthcare 38111.9 About  
GlobalData 38211.10 Disclaimer 382

# List Of Tables in PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

## 1.1 List of Tables

Table 1: Leading Causes of HF 27

Table 2: A Summary of the Compensatory Mechanisms in HF 28

Table 3: The Two Main Classification Systems in HF 33

Table 4: Typical Symptoms of HF 34

Table 5: Risk Factors and Comorbidities for HF 39

Table 6: NYHA Functional Classes I-IV 44

Table 7: ACCF/AHA Stages A, B, C, and D 44

Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of HF Diagnosed Incident Cases 45

Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast of Chronic HF Diagnosed Prevalent Cases 46

Table 10: 7MM, Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases of Chronic HF According to the NYHA Functional Classes I-IV 47

Table 11: 7MM, Sources of Epidemiological Data Used for Forecast of HF Diagnosed Incident Cases of Acute HF Hospitalizations 48

Table 12: 7MM, Sources Not Used in Epidemiological Analysis of HF 63

Table 13: 7MM, Diagnosed Incident Cases of HF, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 64

Table 14: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N (Row %), 2015 66

Table 15: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages  $\geq 45$  Years, N (Row %), 2015 68

Table 16: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 73

Table 17: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 75

Table 18: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 78

Table 19: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N (Row %), 2015 80

Table 20: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages  $\geq 45$  Years, N (Row %), 2015 82

Table 21: Guideline Recommended Tests for the Diagnosis of HF 92

Table 22: Common Factors that Precipitate Acute HF 94

Table 23: Treatment Guidelines for HF 95

Table 24: Comparison of the ACCF/AHA and NYHA HF Classification Systems 96

Table 25: Most Prescribed Drugs for HF by Class in the Global Markets, 2015 97



Table 26: Country Profile for HF - US	107
Table 27: Country Profile for HF - 5EU	110
Table 28: Country Profile for HF - Japan	113
Table 29: Efficacy of Enalapril	118
Table 30: Efficacy of Perindopril	120
Table 31: Global Sales Forecasts (\$M) for ACE inhibitors, 2015-2025	122
Table 32: Global Sales Forecasts (\$M) for ARBs, 2015-2025	126
Table 33: Product Profile - Entresto	133
Table 34: Efficacy of Entresto	134
Table 35: Safety of Entresto	136
Table 36: Entresto SWOT Analysis, 2015	138
Table 37: Global Sales Forecasts (\$M) for Entresto, 2015-2025	141
Table 38: Global Sales Forecasts (\$M) for Diuretics in the Chronic HF Market, 2015-2025	145
Table 39: Global Sales Forecasts (\$M) for Loop Diuretics in the Acute HF Market, 2015-2025	145
Table 40: Global Sales Forecasts (\$M) for Beta Blockers, 2015-2025	150
Table 41: Product Profile - Ivabradine	153
Table 42: Efficacy of Ivabradine	154
Table 43: Ivabradine SWOT Analysis, 2015	156
Table 44: Global Sales Forecasts (\$M) for Procoralan/Corlanor (ivabradine), 2015-2025	158
Table 45: Global Sales Forecasts (\$M) for MRAs, 2015-2025	162
Table 46: Global Sales Forecasts (\$M) for Digoxin, 2015-2025	165
Table 47: Unmet Needs and Opportunities in HF	169
Table 48: Target Opportunity Profile for Acute HF	171
Table 49: Target Opportunity Profile for HF-PEF	175
Table 50: Target Opportunity Profile for HF-REF	178
Table 51: Chronic HF Comorbidities in the 7MM	192
Table 52: Comparison of Therapeutic Classes in Development for HF, 2015	212
Table 53: Product Profile - Serelaxin	215
Table 54: Efficacy of Serelaxin	217
Table 55: Serelaxin SWOT Analysis, 2015	220
Table 56: Global Sales Forecasts (\$M) for Serelaxin, 2015-2025	221

Table 57: Product Profile - Ularitide	224
Table 58: Safety of Ularitide	226
Table 59: Ularitide SWOT Analysis, 2015	228
Table 60: Global Sales Forecasts (\$M) for Ularitide, 2015-2025	229
Table 61: Product Profile - OM	232
Table 62: Efficacy of OM	233
Table 63: OM SWOT Analysis, 2015	236
Table 64: Global Sales Forecasts (\$M) for OM (Chronic HF), 2015-2025	237
Table 65: Global Sales Forecasts (\$M) for OM (Acute HF), 2015-2025	238
Table 66: Product Profile - Vericiguat	240
Table 67: Efficacy of Vericiguat	241
Table 68: Safety of Vericiguat	242
Table 69: Vericiguat SWOT Analysis, 2015	244
Table 70: Global Sales Forecasts (\$M) for vericiguat, 2015-2025	245
Table 71: Product Profile - Finerenone	247
Table 72: Finerenone SWOT Analysis, 2015	250
Table 73: Product Profile - Neucardin	252
Table 74: Neucardin SWOT Analysis, 2015	255
Table 75: Product Profile - Revatio	256
Table 76: Efficacy of Revatio	257
Table 77: Revatio SWOT Analysis, 2015	259
Table 78: Drugs in Development, 2015	262
Table 79: Key Companies in the HF Market in the 7MM, 2015-2025	264
Table 80: Novartis' HF Portfolio Assessment, 2015	268
Table 81: Serviers' HF Portfolio Assessment, 2015	270
Table 82: Cardiorentis' HF Portfolio Assessment, 2015	272
Table 83: Bayer's HF Portfolio Assessment, 2015	274
Table 84: Cytokinetics' HF Portfolio Assessment, 2015	275
Table 85: Global Sales Forecasts (\$M) for Chronic HF, 2015-2025	277
Table 86: Global Sales Forecasts (\$M) for Acute HF, 2015-2025	279
Table 87: HF Global Market - Drivers and Barriers, 2015-2025	281

Table 88: Sales Forecasts (\$M) for HF in the US, 2015-2025	287
Table 89: Key Events Impacting Sales for HF in the US, 2015-2025	289
Table 90: US HF Market - Drivers and Barriers, 2015-2025	290
Table 91: Sales Forecasts (\$M) for HF in France, 2015-2025	293
Table 92: Key Events Impacting Sales for HF in France, 2015-2025	295
Table 93: French HF market - Drivers and Barriers, 2015-2025	296
Table 94: Sales Forecasts (\$M) for HF in Germany, 2015-2025	298
Table 95: Key Events Impacting Sales for HF in Germany, 2015-2025	300
Table 96: Germany HF market - Drivers and Barriers, 2015-2025	301
Table 97: Sales Forecasts (\$M) for HF in Italy, 2015-2025	303
Table 98: Key Events Impacting Sales for HF in Italy, 2015-2025	305
Table 99: Italy HF market - Drivers and Barriers, 2015-2025	306
Table 100: Sales Forecasts (\$M) for HF in Spain, 2015-2025	308
Table 101: Key Events Impacting Sales for HF in Spain, 2015-2025	310
Table 102: Spain HF market - Drivers and Barriers, 2015-2025	311
Table 103: Sales Forecasts (\$M) for HF in the UK, 2015-2025	313
Table 104: Key Events Impacting Sales for HF in the UK, 2015-2025	315
Table 105: UK HF market - Drivers and Barriers, 2015-2025	316
Table 106: Sales Forecasts (\$M) for HF in Japan, 2015-2025	318
Table 107: Key Events Impacting Sales for HF in Japan, 2015-2025	321
Table 108: Japan HF market - Drivers and Barriers, 2015-2025	321
Table 109: Key Launch Dates	366
Table 110: Key Patent Expiries	366
Table 111: High-Prescribing Physicians (non-KOLs) Surveyed, By Country	378

# List Of Figures, Charts and Diagrams in PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

## 1.2 List of Figures

Figure 1: RAAS Mechanism of Action 30

Figure 2: 7MM, Diagnosed Incident Cases of HF, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 65

Figure 3: 7MM, Diagnosed Incident Cases of HF by Age Group, Both Sexes, N, 2015 67

Figure 4: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages  $\geq 45$  Years, N, 2015 69

Figure 5: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Ages  $\geq 45$  Years, by Sex, 2015 70

Figure 6: 7MM, Diagnosed Incident Cases of HF Segmented by EF, Ages  $\geq 45$  Years, Both Sexes, N, 2015 71

Figure 7: 7MM, Diagnosed Incident Cases of HF Segmented by Ventricular Dysfunction, Ages  $\geq 45$  Years, Both Sexes, N, 2015 72

Figure 8: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 73

Figure 9: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages  $\geq 45$  Years, Both Sexes, N, 2015 74

Figure 10: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 76

Figure 11: 7MM, Hospital Length Of Stay For Acute HF Hospitalization, Ages  $\geq 45$  Years, Both Sexes, Days, 2015 77

Figure 12: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages  $\geq 45$  Years, Both Sexes, N, 2015-2025 79

Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N, 2015 81

Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages  $\geq 45$  Years, N, 2015 83

Figure 15: 7MM, Age-Standardized Diagnosed Prevalence of Chronic HF (%), Ages  $\geq 45$  Years, by Sex, 2015 84

Figure 16: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by EF, Ages  $\geq 45$  Years, Both Sexes, N, 2015 85

Figure 17: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by NYHA Classes, Ages  $\geq 45$  Years, Both Sexes, N, 2015 86

Figure 18: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by ACCF/AHA Stages, Ages  $\geq 45$  Years, Both Sexes, N, 2015 87

Figure 19: 7MM, Prevalent Cases of Comorbidities Among Diagnosed Prevalent Cases of Chronic HF, Both Sexes, Ages  $\geq 45$  Years, N, 2015 88

Figure 20: HF treatment based on ACCF/AHA Stage 101

Figure 21: HF - Phase II-III Pipeline, 2015 210

Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in HF, 2015-2025 211

Figure 23: Company Portfolio Gap Analysis in HF, 2015-2025 265

Figure 24: Global Sales for Chronic HF by Region, 2015-2025 278

Figure 25: Global Sales for Acute HF by Region, 2015-2025 280

Figure 26: Sales for Chronic HF in the US by Drug Class, 2015-2025 288

Figure 27: Sales for Acute HF in the US by Drug Class, 2025\* 289

Figure 28: Sales for Chronic HF in France by Drug Class, 2015-2025 294

Figure 29: Sales for Acute HF in France by Drug Class, 2025\* 295

Figure 30: Sales for Chronic HF in Germany by Drug Class, 2015-2025 299

Figure 31: Sales for Acute HF in Germany by Drug Class, 2025\* 300

Figure 32: Sales for Chronic HF in Italy by Drug Class, 2015-2025 304

Figure 33: Sales for Acute HF in Italy by Drug Class, 2025\* 305

Figure 34: Sales for Chronic HF in Spain by Drug Class, 2015-2025 309

Figure 35: Sales for Acute HF in Spain by Drug Class, 2025\* 310

Figure 36: Sales for Chronic HF in the UK by Drug Class, 2015-2025 314

Figure 37: Sales for Acute HF in the UK by Drug Class, 2025\* 315

Figure 38: Sales for Chronic HF in Japan by Drug Class, 2015-2025 319

Figure 39: Sales for Acute HF in Japan by Drug Class, 2015-2025 320

# How to Buy...

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27045>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$10995** | Single User Price
- \$21990** | Site License Price
- \$32985** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.